Skip to content
ESPT
MARKETS / NASDAQ / Health care / Pharmaceuticals / PHAR
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Pharming Group N.v. PHAR

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$376.1M
▲ 26.6% YoY
$2.9M
$54.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

In 2025, RUCONEST generated revenue of $317.9 million, a 26% increase compared to 2024. It has developed a cGMP-validated methodology for producing C1 esterase inhibitor in which its manufacturing process uses transgenic rabbits to produce the recombinant human protein in their milk. Joenja (leniolisib) is an oral phosphoinositide 3-kinase delta inhibitor approved for activated phosphoinositide 3-kinase delta syndrome in the United States, United Kingdom, Australia and Israel for adult and pediatric patients 12 years of age and older, and in Japan for adult and pediatric patients aged 4 years and older. In 2025, Joenja generated revenue of $58.2 million, a 29% increase compared to 2024.

Written from the business description in Pharming Group N.V.'s annual report to the U.S. Securities and Exchange Commission, filed 2 April 2026. Every sentence was checked against that document before publication.

Growth

USD 376.1M
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2025 · Revenue 376.1 · Net income 2.9
150M300M
2018202120242025
Compound annual growth
+22.3%
+12.1%
−40.5%
−40.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +12.1% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

1 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 6.9% · Net 0.7%
10%20%30%-2%-4%
201820212025
ROE
FY2025 · ROE 1.1%
0.5%1.0%-2.0%-4.0%
201820212025
Three returns, three denominators.
Gross margin87.9%
Operating margin6.9%
Net margin0.7%
EBITDA·

Each USD of equity produced 1 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 54.0
30M60M-10M-20M
201820212025
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 500.0M
CashUSD 145.3M
Current ratio2.59×

Not available: we don't have the total debt figure for this period.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
PHAR, 8-year financial record
Metric 20252024202320222021202020192018
Revenue $B0.40.30.20.20.20.20.2◌
Operating income $B0.0−0.0−0.00.00.00.10.1◌
EBITDA $B◌◌◌◌0.00.10.10.0
Income tax $B0.00.0−0.00.00.00.00.0◌
Net income $B0.0−0.0−0.00.00.00.00.0◌
Free cash flow $B0.1−0.0−0.00.00.00.10.10.0
EPS, diluted $0.00−0.02−0.020.020.020.060.06◌
Dividend / sh $◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————
ROE %1.1−5.4−5.0◌◌◌◌◌
Shares out B0.700.680.670.660.650.640.630.62

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 2 failures in 39 reconciliationsAUDITED

Reconciled in 7 of the 8 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 11 checks were skipped: EPS is not tagged before 2018. 11 checks were skipped: revenue is not tagged before 2018.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency2 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code P7
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image